Literature DB >> 9050360

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.

D C Mohr1, D E Goodkin, W Likosky, N Gatto, L K Neilley, C Griffin, B Stiebling.   

Abstract

This study, conducted in three separate outpatient health care delivery settings, examined the therapeutic expectations of patients with multiple sclerosis (MS) before they initiated interferon beta-1b therapy, the results of current educational procedures to correct unrealistic expectations, and the relationship between post-education expectations and discontinuing therapy. Ninety-nine consecutive patients were seen in a university based outpatient MS clinic, an academic group practice outpatient MS clinic, or a health maintenance organization outpatient neurology clinic. Before the educational sessions, 57% of the patients expressed unrealistically optimistic expectations regarding reduction in attack rate and 34% expressed unrealistically optimistic expectations regarding improvement in functional status. Educational procedures significantly altered unrealistic expectations but the results were sub-optimal since 33% of the patients maintained overly optimistic expectations regarding reduction in attack rate. Post-education unrealistic expectations of improvement in functional status were significantly related to discontinuing therapy within 6 months. Three adverse effects of therapy also were related independently to adherence to treatment: depression and flu-like symptoms were related to discontinuing therapy while soreness at injection site was related to continuing therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9050360     DOI: 10.1177/135245859600200502

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  30 in total

1.  Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.

Authors:  Mary L Filipi; Jill Beavin; Raquel T Brillante; Kathleen Costello; Gail C Hartley; Kay Hartley; Marie Namey; Shirley O'Leary; Gina Remington
Journal:  Int J MS Care       Date:  2014

Review 2.  [Adherence to neurologic treatment. Lessons from multiple sclerosis].

Authors:  S Kern; H Reichmann; T Ziemssen
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

3.  QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.

Authors:  Tjalf Ziemssen; Pasquale Calabrese; Iris-Katharina Penner; Rainer Apfel
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

4.  Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwait.

Authors:  Raed Alroughani; Anil Thussu
Journal:  Int J MS Care       Date:  2012

5.  The evolving role of the multiple sclerosis nurse: an international perspective.

Authors:  Therese Burke; Sara Dishon; Lynn McEwan; Jennifer Smrtka
Journal:  Int J MS Care       Date:  2011

6.  Identification of Beck Depression Inventory items related to multiple sclerosis.

Authors:  D C Mohr; D E Goodkin; W Likosky; L Beutler; N Gatto; M K Langan
Journal:  J Behav Med       Date:  1997-08

7.  Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.

Authors:  M R Kraus; A Schäfer; H Csef; H Faller; H Mörk; M Scheurlen
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

8.  Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Authors:  June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy
Journal:  Int J MS Care       Date:  2016 Jul-Aug

9.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

Review 10.  [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].

Authors:  Elisabeth Fertl; Martin Krichmayr
Journal:  Wien Med Wochenschr       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.